A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Capmatinib (Primary) ; Nazartinib (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Oct 2018 This trial has been completed in Netherlands.
- 22 Feb 2018 Planned End Date changed from 10 Apr 2022 to 11 Apr 2022.
- 22 Feb 2018 Planned primary completion date changed from 17 Jun 2021 to 11 Apr 2022.